Please login to the form below

Not currently logged in
Email:
Password:

Prevnar

This page shows the latest Prevnar news and features for those working in and with pharma, biotech and healthcare.

Pfizer names next CEO as Read retires

Pfizer names next CEO as Read retires

and an expected continued decline in sales of vaccine Prevnar.

Latest news

  • Pfizer’s Prevnar-13 successor takes aim at Merck rival Pfizer’s Prevnar-13 successor takes aim at Merck rival

    is in pursuit of PCV-15 (also known as V114), a 15-valent candidate that Merck is bringing to market to compete with Pfizer’s established pneumococcal vaccine Prevnar-13, which ... pair. However, it fell a little short in infant studies, failing to

  • Pfizer’s flat sales focus investor attention on M&A Pfizer’s flat sales focus investor attention on M&A

    Once again, cancer drug Ibrance (palbociclib), anticoagulant Eliquis (apixaban) and Xeljanz (tofacitinib) for arthritis and other immunological indications led the charge, backed up by a solid advance for paediatric vaccine Prevnar ... Vaccines for

  • Pfizer split still on cards - for tax reasons Pfizer split still on cards - for tax reasons

    cancer therapy Ibrance (palbociclib), arthritis therapy Xeljanz (tofacitinib) and Prevnar pneumonia vaccine family. ... Prevnar grew 16% to top $1.5bn in the quarter, helped by a new indication for use in adults, which added $439m as well as a $40m

  • Soaring sales of Pfizer's Prevnar lead to calls for price cut Soaring sales of Pfizer's Prevnar lead to calls for price cut

    Pfizer has reported a hefty increase in sales of its Prevnar family of pneumonia vaccines, prompting medical charities to call for a price cut. ... Aside from Prevnar, rheumatoid arthritis treatment Xeljanz (tofacitinib) also performed well - rising 66%

  • Pfizer falls as strong dollar and generic erosion bites Pfizer falls as strong dollar and generic erosion bites

    Pfizer's global vaccines sales saw the best growth with sales rising 44% to $1.33bn, predominately on the back of the Prevnar family of inoculations. .

More from news
Approximately 5 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    This was driven largely by higher-than-expected sales of its pneumonia vaccine, Prevnar, which accounted for more than 11% of its total revenues in the third quarter of 2017.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics